Innovative Pharmaceutical Biotech Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 0/6

Innovative Pharmaceutical Biotech hat ein Gesamteigenkapital von HK$333.1M und eine Gesamtverschuldung von HK$1.0B, was einen Verschuldungsgrad von 312.7% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen HK$1.4B bzw. HK$1.0B.

Wichtige Informationen

312.7%

Verhältnis von Schulden zu Eigenkapital

HK$1.04b

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	HK$862.00k
Eigenkapital	HK$333.07m
Gesamtverbindlichkeiten	HK$1.05b
Gesamtvermögen	HK$1.38b

Jüngste Berichte zur Finanzlage

Innovative Pharmaceutical Biotech (HKG:399) Has Debt But No Earnings; Should You Worry?

Aug 12

Is Innovative Pharmaceutical Biotech (HKG:399) Using Too Much Debt?

Feb 18

Recent updates

Innovative Pharmaceutical Biotech (HKG:399) Has Debt But No Earnings; Should You Worry?

Aug 12

Robust Earnings May Not Tell The Whole Story For Innovative Pharmaceutical Biotech (HKG:399)

Jan 05

Is Innovative Pharmaceutical Biotech (HKG:399) Using Too Much Debt?

Feb 18

Innovative Pharmaceutical Biotech's(HKG:399) Share Price Is Down 80% Over The Past Five Years.

Nov 26

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: 399Die kurzfristigen Aktiva des Unternehmens (HK$8.8M) decken seine kurzfristigen Passiva (HK$378.0M) nicht.

Langfristige Verbindlichkeiten: 399Die kurzfristigen Vermögenswerte des Unternehmens (HK$8.8M) decken seine langfristigen Verbindlichkeiten (HK$671.2M) nicht.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: 399Die Nettoverschuldung im Verhältnis zum Eigenkapital (312.4%) wird als hoch angesehen.

Schulden abbauen: 399Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 77.9% auf 312.7% gestiegen.

Schuldendeckung: 399Der operative Cashflow des Unternehmens ist negativ, so dass die Schulden nicht ausreichend gedeckt sind.

Zinsdeckung: Es liegen nicht genügend Daten vor, um festzustellen, ob die Zinszahlungen von 399 auf seine Schulden durch EBIT gut gedeckt sind.

Innovative Pharmaceutical Biotech Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Innovative Pharmaceutical Biotech (HKG:399) Has Debt But No Earnings; Should You Worry?

Innovative Pharmaceutical Biotech Ordinary Shares to Be Deleted from Other OTC

Is Innovative Pharmaceutical Biotech (HKG:399) Using Too Much Debt?

Recent updates

Innovative Pharmaceutical Biotech Limited to Report Fiscal Year 2024 Results on Jun 28, 2024

Innovative Pharmaceutical Biotech Limited has filed a Follow-on Equity Offering in the amount of HKD 19.95 million.

First half 2024 earnings released: EPS: HK$0.13 (vs HK$0.079 loss in 1H 2023)

New major risk - Financial position

Innovative Pharmaceutical Biotech Limited Provides Unaudited Earnings Guidance for the Six Months Ended 30 September 2023

Innovative Pharmaceutical Biotech Limited to Report First Half, 2024 Results on Nov 29, 2023

Innovative Pharmaceutical Biotech Limited (SEHK:399) entered into a memorandum of understanding to acquire a majority interest in Niraxx Light Therapeutics, Inc.

New minor risk - Share price stability

Innovative Pharmaceutical Biotech (HKG:399) Has Debt But No Earnings; Should You Worry?

Full year 2023 earnings released: HK$0.17 loss per share (vs HK$0.031 profit in FY 2022)

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 30, 2023

Innovative Pharmaceutical Biotech Limited Appoints Cheng Tak Yiu as an Executive Director

Full year 2023 earnings released: HK$0.17 loss per share (vs HK$0.031 profit in FY 2022)

Innovative Pharmaceutical Biotech Limited to Report Fiscal Year 2023 Results on Jun 29, 2023

First half 2023 earnings released: HK$0.079 loss per share (vs HK$0.085 profit in 1H 2022)

First half 2023 earnings released: HK$0.079 loss per share (vs HK$0.085 profit in 1H 2022)

Innovative Pharmaceutical Biotech Limited Provides Earnings Guidance for the Six Months Ending 30 September 2022

Innovative Pharmaceutical Biotech Limited to Report First Half, 2023 Results on Nov 29, 2022

Less than half of directors are independent

Full year 2022 earnings released: EPS: HK$0.031 (vs HK$0.14 loss in FY 2021)

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 30, 2022

Innovative Pharmaceutical Biotech Ordinary Shares to Be Deleted from Other OTC

Full year 2022 earnings released

Innovative Pharmaceutical Biotech Limited to Report Fiscal Year 2023 Results on Jun 29, 2022

Less than half of directors are independent

Robust Earnings May Not Tell The Whole Story For Innovative Pharmaceutical Biotech (HKG:399)

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Innovative Pharmaceutical Biotech Limited Provides Earnings Guidance for the Six Months Ending September 30, 2021

Full year 2021 earnings released: HK$0.14 loss per share (vs HK$0.14 loss in FY 2020)

New 90-day high: HK$0.28

Is Innovative Pharmaceutical Biotech (HKG:399) Using Too Much Debt?

Innovative Pharmaceutical Biotech Limited Announces Executive Changes

New 90-day low: HK$0.24

First half 2021 earnings released: HK$0.064 loss per share

New 90-day low: HK$0.24

First half 2021 earnings released: HK$0.064 loss per share

Innovative Pharmaceutical Biotech's(HKG:399) Share Price Is Down 80% Over The Past Five Years.

Innovative Pharmaceutical Biotech Limited to Report First Half, 2021 Results on Nov 27, 2020

Innovative Pharmaceutical Biotech Limited Announces Board Changes

New 90-day high: HK$0.27

New 90-day high - HK$0.26

Mao Yumin completed the acquisition of 19.14% stake in Extrawell Pharmaceutical Holdings Limited (SEHK:858) from Innovative Pharmaceutical Biotech Limited (SEHK:399).

Full year earnings released - HK$0.14 loss per share

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen